dcsimg Life Sciences

Life Sciences

Emerging, middle-market and established companies alike require sophisticated legal representation that is cost-effective and capable of responding to the rapidly changing demands of regulators and customers. As counsel to domestic and global life sciences companies at every stage of development, the Life Sciences industry group at McGuireWoods offers clients a single, coordinated team of lawyers with deep, varied experience. Our clients recognize that they are treated as firm clients and not as those of a single practitioner or office location.

We counsel clients in all major areas of law affecting life sciences businesses and at every step in the product lifecycle. We provide guidance on corporate transactions and matters involving company structure and formation, financing, facilities acquisition and leasing, and vendor contracts. We have extensive experience in healthcare and life sciences-related regulatory requirements, including compliance audits and policies, FDA notification and approvals, development of pricing programs, and reimbursement and third-party payor processes.

Regulatory policies walk hand in hand with legislative mandates. In conjunction with our full-service public affairs subsidiary, McGuireWoods Consulting, we provide strategic communications and government relations guidance that helps businesses and industry coalitions shape pending legislation and respond to state and federal initiatives.

When disputes or law enforcement investigations arise, we provide aggressive defense against allegations of theft, product liability and mass torts. We represent clients facing government inquiries and administrative actions involving a broad range of issues, from securities disclosures and financial accounting rules to data privacy, antitrust and other compliance requirements. We also investigate and vigorously pursue counterfeiters, gray marketers and abusers of supply chain systems.

As life sciences businesses grow and transform, capital sourcing and other forms of financing become an important concern. We represent clients in negotiations with private equity investors, commercial banks and other financial institutions. Similarly, our depth of experience in public offerings and middle-market mergers and acquisitions adds value to growth and technology companies when exploring liquidity events.

While life sciences businesses share many of the same concerns as companies in other industries, these issues must be addressed in the context of this highly regulated sector of the economy. Our multidisciplinary team of lawyers provides broad-spectrum, coordinated counsel on all major areas of law affecting clients’ operations and strategy. These core areas of service include labor and employment, intellectual property, state and local taxation, and international trade. Our experience in these and other areas of law enables us to provide prompt, effective counsel in the dynamic life sciences marketplace.

CONTACTS

Timothy H. Kratz Partner T: +1 404 443 5730
Kathleen H. Dooley Partner T: +1 704 343 2347
Raj Natarajan Partner T: +1 704 343 2330

BLOG

FDA Life

Results 1-20 of 130
Show All

RESULTS DEPEND ON A VARIETY OF FACTORS UNIQUE TO EACH CASE. PRIOR RESULTS DO NOT GUARANTEE OR PREDICT A SIMILAR OUTCOME.

Representative Matter

World-class academic and health care system

Represent world-class academic and health care system in multi-plaintiff litigation arising from allegations that falsified genomic research was allowed to proceed to clinical trials with the enrollment and treatment of cancer patients.
Representative Matter

Canadian-based company

Assisted a Canadian-based company to register its establishment with FDA and evaluate FDA’s mobile medical application guidances for classification of its activity monitor device adapted for rehabilitative use, which incorporated smartphone application connectivity and monitoring.
Representative Matter

Biosimilar manufacturer

Assisted biosimilar manufacturer with developing clinical trial strategies for approval, which included considering biosimilar approvals in other countries, such as possible 505(b)(2) NDA approval strategies.
Representative Matter

Large U.S. pharmaceutical company

Advising a large U.S. pharmaceutical company on the separation of the UK subsidiary from its U.S. parent company, with respect to the introduction of new benefit plans and secondment arrangements for the CEO.
Representative Matter

Mezzanine fund

Represented a provider of mezzanine capital in its mezzanine investment in a lab company, which the lab company used to help fund an acquisition.  
Representative Matter

Major dietary ingredient manufacturer

Provide assistance to a major dietary ingredient manufacturer with reviewing food and dietary supplement labeling for compliance with FDA regulations and requirements, including Dietary Supplement Health and Education Act (DSHEA) requirements and structure/function claims.
Representative Matter

One of the world's leading suppliers to the life science industries

Represented one of the world's leading suppliers to the life science industries, based in Switzerland, in the acquisition by tender offer of an NYSE-traded chemicals company for $1.2 billion.
Representative Matter

Indiana-based bank owned SBIC Fund

Representation of an Indiana-based bank owned SBIC Fund on a bridge financing in a developer of drugs for ovarian and lung tumors.
Representative Matter

Leading generic and specialty pharmaceutical company

After a three week jury trial, obtained a unanimous defense verdict for one of the world's leading generic and specialty pharmaceutical companies.
Representative Matter

Leading generic and specialty pharmaceutical company

Representation of a pharmaceutical manufacturer in a wrongful death case, obtaining a defense verdict after an hour of deliberation.
Representative Matter

Generic drug manufacturer

Assisted generic drug manufacturer in abbreviated new drug application (ANDA) patent litigation related to advertising and promotion material for marketed products, including reviews by the Division of Prescription Drug Promotion (OPDP) with regard to the listing or assertion of method-of-use patents.
Representative Matter

Major life sciences organization

Advising on UK data protection requirements in relation to medical research and patient records for drug trials, working as part of a team of European lawyers to provide coordinated advice to a major life sciences organisation.
Representative Matter

Large U.S. pharmaceutical company

Advising a large US pharmaceutical company on the removal of its UK head of legal, following allegations of harassment and personal injury.
Representative Matter

Major drug manufacturer

Provide assistance to a major drug manufacturer with drafting citizen petitions to FDA regarding generic drug formulations and testing.
Representative Matter

Medical device manufacturer

Provide assistance to medical device manufacturer with determining appropriate classification for their proposed devices, including assisting with their 510(k) clearances and premarket approval applications (PMAs).
Representative Matter

Generic drug manufacturer

Assisted generic drug manufacturer with obtaining samples for products and develop shared or separate risk evaluation and mitigation strategies (REMS)

Representative Matter

Generic drug manufacturer

Provide assistance to a generic drug manufacturer with developing strategy for administrative proceedings including filing or responding to citizen petitions and challenging FDA review decision prior to filing legal action against the FDA.
Representative Matter

Major pharmaceutical manufacturer

Assisted major pharmaceutical manufacturer in developing clinical strategy and participating in FDA meetings to obtain new approval.
Representative Matter

Fortune 500 pharmaceutical company

Represented a Fortune 500 pharmaceutical company in negotiating Microsoft's Business Agreement, Enterprise Agreement, Service Agreement and Select Agreement.  
Representative Matter

Administrative agent and lead arranger

Represented the administrative agent and lead arranger in connection with a $47 million senior secured credit facility for a leveraged buyout of a suture products distributor.
Results 1-20 of 130
Results 1-25 of 93
Show All
Brad Alexander Brad L. Alexander
Sr. VP and Director, Georgia Gov. Relations McGuireWoods Consulting LLC
Promenade
1230 Peachtree Street, N.E.
Suite 2100
Atlanta, GA 30309-3534

T: +1 404 443 5811
F: +1 404 443 5682
vCard
Ashley Allen Ashley K. Allen
Counsel
One James Center
901 East Cary Street
Richmond, VA 23219-4030

T: +1 804 775 1918
F: +1 804 775 1061
vCard
Mark E Anderson Mark E. Anderson
Partner
434 Fayetteville Street
Suite 2600
Raleigh, NC 27601

1345 Avenue of the Americas
7th Floor
New York, NY 10105-0106

T: +1 919 755 6678
F: +1 919 755 6581
vCard
George J Barry III George J. Barry III
Partner
Promenade
1230 Peachtree Street, N.E.
Suite 2100
Atlanta, GA 30309-3534

T: +1 404 443 5734
F: +1 404 443 5753
vCard
Evan Bayh Evan Bayh
Partner
2001 K Street N.W.
Suite 400
Washington, DC 20006-1040

T: +1 202 828 2825
F: +1 202 828 3331
vCard
Scott Becker Scott Becker
Partner
77 West Wacker Drive
Suite 4100
Chicago, IL 60601-1818

T: +1 312 750 6016
F: +1 312 920 6135
vCard
Maurice A Bellan Maurice A. Bellan
Partner
2001 K Street N.W.
Suite 400
Washington, DC 20006-1040

7 Saint Paul Street
Suite 1000
Baltimore, MD 21202-1671

T: +1 202 857 2400
F: +1 202 828 2981
vCard

T:+1 410 659 4438
F: +1 410 659 4599

Samuel C Bernstein Samuel C. Bernstein
Associate
77 West Wacker Drive
Suite 4100
Chicago, IL 60601-1818

T: +1 312 849 8222
F: +1 312 698 4571
vCard
Micheal L Binns Micheal L. Binns
Associate
Promenade
1230 Peachtree Street, N.E.
Suite 2100
Atlanta, GA 30309-3534

T: +1 404 443 5748
F: +1 404 443 5698
vCard
William J Boddy William J. Boddy
Associate
11 Pilgrim Street
London EC4V 6RN
United Kingdom

T: +44 20 7632 1625
F: +44 20 7632 1638
vCard
Ginny Boland Ginny Boland
Asst. VP, Strategic Communications McGuireWoods Consulting LLC
One James Center
901 East Cary Street
Richmond, VA 23219-4030

T: +1 804 775 1907
F: +1 804 775 1061
vCard
Ryan Bonistalli Ryan E. Bonistalli
Associate
One James Center
901 East Cary Street
Richmond, VA 23219-4030

T: +1 804 775 1014
F: +1 804 698 2036
vCard
Alex J Brackett Alex J. Brackett
Partner
One James Center
901 East Cary Street
Richmond, VA 23219-4030

T: +1 804 775 4749
F: +1 804 698 2089
vCard
Bryan C Brantley Bryan C. Brantley
Partner
EQT Plaza
625 Liberty Avenue
23rd Floor
Pittsburgh, PA 15222-3142

T: +1 412 667 7983
F: +1 412 667 7971
vCard
Brie Buchanan Brie L.B. Buchanan
Associate
Promenade
1230 Peachtree Street, N.E.
Suite 2100
Atlanta, GA 30309-3534

T: +1 404 443 5709
F: +1 404 443 5760
vCard
Meggan Michelle Bushee Meggan Michelle Bushee
Associate
201 North Tryon Street
Suite 3000
Charlotte, NC 28202-2146

T: +1 704 343 2360
F: +1 704 805 5085
vCard
William Bushman William G. Bushman
Associate
One James Center
901 East Cary Street
Richmond, VA 23219-4030

T: +1 804 775 1806
F: +1 804 775 1061
vCard
Holly Carnell Holly Carnell
Associate
77 West Wacker Drive
Suite 4100
Chicago, IL 60601-1818

T: +1 312 849 3687
F: +1 312 698 4504
vCard
Karen L Carroll Karen L. Carroll
Associate
Promenade
1230 Peachtree Street, N.E.
Suite 2100
Atlanta, GA 30309-3534

T: +1 404 443 5620
F: +1 404 443 5757
vCard
Andrew J Cataldo Andrew J. Cataldo
Partner
Promenade
1230 Peachtree Street, N.E.
Suite 2100
Atlanta, GA 30309-3534

T: +1 404 443 5725
F: +1 404 443 5795
vCard
Jeffrey J Chapman Jeffrey J. Chapman
Partner
1345 Avenue of the Americas
7th Floor
New York, NY 10105-0106

T: +1 212 548 7060
F: +1 212 715 6277
vCard
Geoffrey C Cockrell Geoffrey C. Cockrell
Partner
77 West Wacker Drive
Suite 4100
Chicago, IL 60601-1818

T: +1 312 849 8272
F: +1 312 698 4572
vCard
J. D Costa J. D. Costa
Associate
201 North Tryon Street
Suite 3000
Charlotte, NC 28202-2146

T: +1 704 343 2236
F: +1 704 353 6192
vCard
Patrick A De Ridder Patrick A. De Ridder
Partner
One James Center
901 East Cary Street
Richmond, VA 23219-4030

11 Pilgrim Street
London EC4V 6RN
United Kingdom

T: +1 804 775 4369
F: +1 804 698 2221
vCard

T:+44 20 7632 1716
F: +44 20 7632 1638

Dorothea W Dickerman Dorothea W. Dickerman
Partner
1750 Tysons Boulevard
Suite 1800
Tysons Corner, VA 22102-4215

2001 K Street N.W.
Suite 400
Washington, DC 20006-1040

T: +1 703 712 5387
F: +1 703 712 5242
vCard

T:+1 202 857 1721
F: +1 202 857 1737

Results 1-20 of 52
Show All
Speaking Engagement

Food, Drug and Cosmetic Law Section Annual Meeting

Thursday, January 29, 2015
New York City, NY
Speaking Engagement

7th Risk Evaluation and Mitigation Strategies Summit

January 22, 2015
Arlington, VA
Speaking Engagement

Climbing the Regulatory Summit

Regulatory and Clinical Trial Quandaries

December 10, 2014
Johns Hopkins University, Montgomery County Campus
Event

6th Annual Medical Device and Life Sciences Conference

November 18, 2014
Chicago, IL
Speaking Engagement

Europe v. U.S. Food, Drug, Device & Tobacco Regulation & Policy

Emerging Issues and Comparative Analysis

November 14, 2014
Brussels
Speaking Engagement

AdvaMed 2014: The MedTech Conference

October 7, 2014
Chicago, IL
Speaking Engagement

Redefining Early Stage Investments

The Case for Small Markets with Large Returns: Orphans/Rare Disease Panel

September 17, 2014
Boston, MA
Speaking Engagement

Legal and Regulatory Summit on Generic Drugs

July 24-25, 2014
New York, NY
Speaking Engagement

5th Annual Conference on Biosimilars

June 4-6, 2014
New York, NY
Event

Healthcare Litigation Conference

May 29, 2014
Richmond, VA
Speaking Engagement

2014 Food and Drug Law Institute Annual Conference

Breakfast Break-out: Career Opportunities in Food & Drug Law

April 24, 2014
Event

Healthcare Litigation Conference

April 8, 2014
Chicago, IL
Speaking Engagement

BioCentury This Week

Safety v. Competition (Federal Trade Commission Follow-On Biologics Workshop: Impact of Recent Legislative and Regulatory Naming Proposals on Competition February 4, 2014 Overview)

February 16, 2014
Speaking Engagement

Montgomery County Department of Economic Development

Biotechnology Roundtable: Innovative Strategies for New Product Development

February 5, 2014
Speaking Engagement

New York State Bar Association's Annual Meeting of the Food, Drug and Cosmetic Law Section

FDA Regulation: The Intersection of Policy and Politics, The Opportunities and Challenges for Innovation – Perspectives from Two Former FDA Officials

January 30, 2014
Speaking Engagement

ExL Pharma's 6th Risk Evaluation and Mitigation Strategies Summit

Understand the FDA Report [Risk Evaluation and Mitigation Strategies ("REMS") Standardization] and the Impact on the Industry

January 28, 2014
Speaking Engagement

Korea-Maryland USA Bio Expo

Current Good Manufacturing Practice (cGMP) and its Role in Regulatory Drug Quality", "Current Drug Shortages and Orphan Drug Disease Pharmaceutical Development", and "Innovative Strategies for New Drug Development/Biobetters

November 8, 2013
Results 1-20 of 52
Results 1-20 of 150
Show All
Legal Alert

EU Medical Device Rules Continue to Progress

FDA Life
May 27, 2014
Legal Alert

EU Medical Device Rules

New Rules Are Nearly There But Not Quite

FDA Life
May 15, 2014
Legal Alert

FDA’s Recent Two-Pronged Attack on Drug Shortages

Four Things to Know about FDA’s Proposed Rule

December 11, 2013
Legal Alert

Drug Quality and Security Act

What You Need to Know

December 4, 2013
Legal Alert

Illinois Expands Penalties for Healthcare Fraud

September 23, 2013
Article

Free Speech and Off-Label Drug Promotion: Should Recent Cases Change Your Business Practices?

Navigating Recent Off-Label Promotion Developments, Understanding Government Relations and the Potential Impact of Noteworthy Cases

(Aspatore Special Report)
September 1, 2013
Brian J. Malkin, Aspatore/Thompson Reuters
Results 1-20 of 150